Recurrent erysipelas despite antibiotic prophylaxis: An analysis from case studies

Netherlands Journal of Medicine

Volumn 65, Issue 3, 2007, Pages 89-94

  Koster, J B ^a   Kullberg, B J ^a   van Der Meer, J W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic prophylaxis; Erysipelas; Prevention; Recurrent

Indexed keywords

AMOXICILLIN; ANTIFUNGAL AGENT; BENZATHINE; BENZATHINE PENICILLIN; CLARITHROMYCIN; CLINDAMYCIN; FLUCLOXACILLIN; PENICILLIN G; PHENETICILLIN; PROCAINE PENICILLIN; ROXITHROMYCIN; VALACICLOVIR;

ADULT; ANTIBIOTIC PROPHYLAXIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYSIPELAS; FEMALE; FOOT CARE; HUMAN; MALE; MEDICATION ERROR; MYCOSIS; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; RETREATMENT; REVIEW; SEROLOGY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CLINDAMYCIN; ERYSIPELAS; ETHYLENEDIAMINES; HUMANS; PENICILLINS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 33947684305     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Mandell GL, Douglas RG, Bennett JE, Dolin R. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone. 2000.
2. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334:240-5.
3. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulits): case-control study. BMJ 1999;318:1591-4.
4. Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987;15:105-6.
5. Duvanel T, Mérot Y, Harms M, et al. Prophylactic antibiotics in erysipelas. Lancet 1985; 1:1401.
6. Kremer M, Zuckerman R, Avraham Z, et al. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infection 1991;22:37-40.
7. Sjöblom AC, Eriksson B, Jorup-Rönström C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993;21:390-3.
8. Bitnun S. Prophylactic antibiotics in recurrent erysipelas. Lancet 1985;1:345.
9. Thind P. Prophylactic antibiotics in recurrent erysipelas. Lancet 1985;1:986.
10. Kerstens PJ, Endtz HP, Meis JF, et al. Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogamma-globulinemia. Eur J Clin Microbiol Infect Dis 1992;11:842-7.
11. Cone LA, Dreisbach PB, Hirschberg J, Secar C, Dreisbach LP, Salatich W. Cellulitis and Septic Arthritis Caused by Campylobacter fetus and Campylobacter jejuni: Report of 2 Cases and Review of the Literature. J Clin Rheumatol 2003;9:362-9.
12. Monselise A, Blickstein D, Ostfeld I, Segal R, Weinberger M. A case of cellulitis complication Campylobacter jejuni subspecies jejuni bacteremia and review of the literature. Eur J Clin Microbiol Infect Dis 2004;23:718-21.
13. Kaplan EL, Berrios X, Speth J, et al. Pharmacokinetics of benzathine penicillin G: Serum levels during the 2g days after intramuscular injection of 1,200,000 units. J Pediatr 1989;115:146-50.
14. Currie BJ, Burt T, Kaplan EL. Penicillin concentrations after increased doses of benzathine penicillin G for prevention of secondary rheumatic fever. Antimicrob Agents Chemother 1994;38:1203-4.
15. Cockshott WP, Thompson GT, Howlett LJ, Seele ET. Intramuscular or intralipomatous injections? N Engl J Med 1982;307:356-8.